BLOG: Epithelium-on cross-linking allows for interventional keratoconus approach

Epioxa obtained FDA approval in October 2025, which makes it the first and only FDA-approved epithelium-on, oxygen-enriched corneal cross-linking treatment for patients with keratoconus. Epioxa (Glaukos) is bioactivated by UV light and designed to improve corneal penetration through an intact epithelium. It is intended to be used with the company’s O2n system, which delivers pulsed